ORKA Oruka Therapeutics, Inc. Insider Trading

Director Carl Dambkowski sold 105,000 shares for $6.2M via 10b5-1 plan; stock down 13.0% in 30 days.

Carl Dambkowski, Director at Oruka Therapeutics, executed three separate sales totaling 105,000 shares (105.0K shares) for $6,191,366.32 ($6.2M) at a blended average price of $58.97 on 2026-05-21, reducing his holdings by 58.7% from 178,743 to 73,743 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The stock has declined 13.0% over the prior 30 days and trades at $60.61, down 33.4% from its 52-week high of $91.00, in a context where the company generated zero revenue in its latest quarter and posted a net loss of $31,820,000 ($-31.8M). Investors should note that while the director's cross-ticker track record shows an average 90-day return of +13.4% following prior sells, that success pattern reflects other holdings and does not address directional conviction at this ticker in particular.

SVP Agarwal sells 10,290 shares of ORKA for $607.8K in 4 scheduled transactions under 10b5-1 plan

Arjun Agarwal, Senior Vice President of Finance, executed 4 separate sales on 2026-05-18 totaling 10,290 shares for $607,806.41 at a blended average price of $59.07. This transaction was executed under a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and not discretionary. Post-transaction, Agarwal holds 16,406 shares, down from 26,696 shares, representing a 38.5% reduction in his holdings. The stock trades at $58.34, down 35.9% from its 52-week high of $91.00, and the company posted $0.00 revenue in the latest quarter with a net loss of $31.8M, indicating ongoing unprofitability. The scheduled nature of this filing precludes attribution of timing intent to the insider.